Bone Therapeutics
-
Financial
Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic
The acquisition will result in the business combination of Bone Therapeutics and Medsenic to create BioSenic, a speciality biopharma company…
Read More » -
Biologics
Bone Therapeutics to strategically focus on lead cell therapy product ALLOB
REGULATED INFORMATION Strategic focus revised and fully focused on achieving topline results of the ALLOB Phase IIb study in tibial…
Read More » -
Biologics
Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB
REGULATED INFORMATION Link Health to be granted global rights for development, manufacturing and commercialization of ALLOB Bone Therapeutics to receive…
Read More » -
Biologics
Bone Therapeutics provides update on the progress of clinical studies
REGULATED INFORMATION JTA-004 Phase III top-line results planned first half September ALLOB Phase IIb currently on track but recruitment slow…
Read More » -
Biologics
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
Gosselies, Belgium, 12 January 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet…
Read More » -
Biologics
Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
Gosselies, Belgium, 14 October 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet…
Read More » -
Biologics
Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia
Gosselies, Belgium, 5 October 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet…
Read More » -
Biologics
Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study
Gosselies, Belgium, 18 May 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high…
Read More » -
Biologics
Bone Therapeutics Provides First Quarter 2020 Business Update
Gosselies, Belgium, 6 May 2020, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the…
Read More » -
Biologics
Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer
Gosselies, Belgium, 26 March 2020, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high…
Read More » -
Financial
Bone Therapeutics announces 2019 full year results
Gosselies, Belgium, 11 March 2020, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing…
Read More » -
Financial
Bone Therapeutics Reports Financial Results for the First Nine Months of 2019 and Provides Third Quarter 2019 Business Update
Gosselies, Belgium, 6 November 2019, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the…
Read More » -
Financial
Bone Therapeutics reports half year 2019 results
Gosselies, Belgium, 30 August 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on…
Read More » -
Biologics
Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure
June 13, 2019 / Source: Bone Therapeutics SA Regulated Information – Inside Information Treatment with ALLOB resulted in significant clinical and radiological improvementsTreatment with…
Read More » -
Financial
Bone Therapeutics Provides First Quarter 2019 Business Update
Gosselies, Belgium, 7 May 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high…
Read More »